Match!
Stefania Bellone
Yale University
CancerUterine serous carcinomaOvarian cancerCancer researchMedicine
118Publications
26H-index
2,107Citations
What is this?
Publications 111
Newest
#1Alessandro D. Santin (Yale University)H-Index: 31
#2Virginia FiliaciH-Index: 8
Last. Barbara M. ButtinH-Index: 9
view all 12 authors...
Source
#1A. Nickles Fader (Johns Hopkins University)H-Index: 31
#2Dana M. Roque (UMB: University of Maryland, Baltimore)H-Index: 14
Last. Nicole S. Nevadunsky (Albert Einstein College of Medicine)H-Index: 11
view all 20 authors...
#1Emanuele Perrone (Yale University)H-Index: 1
#1Emanuele Perrone (Yale University)H-Index: 7
Last. Alessandro D. Santin (Yale University)H-Index: 31
view all 22 authors...
Endometrial cancer is the most common gynecologic malignancy in developed countries. The antibody-drug conjugate (ADC) sacituzumab govitecan (SG) targets trophoblast cell-surface antigen-2 (Trop-2) - a cell-surface glycoprotein highly expressed in many epithelial tumors - and delivers the active metabolite of irinotecan SN-38 to Trop-2-positive tumor cells. We evaluated Trop-2 expression in endometrial endometrioid carcinoma (EC) tissues and the activity of SG against primary poorly differentiat...
1 CitationsSource
#1Silvia PelligraH-Index: 1
#2Natalia Buza (Yale University)H-Index: 20
Last. Alessandro D. SantinH-Index: 31
view all 9 authors...
Abstract Background Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment of advanced or recurrent HER2/Neu+ USC per NCCN guidelines. Case: We describe two USC patients with overexpression of HER2/neu at 2+/3+ level by immunohistochemistry and c-erbB2 gene amplifica...
Source
#1Emanuele Perrone (Yale University)H-Index: 1
#1Emanuele PerroneH-Index: 7
Last. Anna BianchiH-Index: 4
view all 22 authors...
Background Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast-antigen-2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver SN-38, the active metabolite of irinotecan. This study aimed to evaluate Trop-2 expression in EOC tissues and the preclinical activity of SG against primary EOC cell lines and xenografts. Methods Trop-2 expression was ass...
Source
#1Salvatore LopezH-Index: 14
#2Emanuele Perrone (Yale University)H-Index: 7
Last. Anna BianchiH-Index: 4
view all 24 authors...
// Salvatore Lopez 1 , 2 , 3 , Emanuele Perrone 1 , Stefania Bellone 1 , Elena Bonazzoli 1 , Burak Zeybek 1 , Chanhee Han 1 , Joan Tymon-Rosario 1 , Gary Altwerger 1 , Gulden Menderes 1 , Anna Bianchi 1 , Luca Zammataro 1 , Aranzazu Manzano 1 , Paola Manara 1 , Elena Ratner 1 , Dan-Arin Silasi 1 , Gloria S. Huang 1 , Masoud Azodi 1 , Peter E. Schwartz 1 , Francesco Raspagliesi 3 , Roberto Angioli 4 , Natalia Buza 5 , Pei Hui 5 , Heather M. Bond 6 and Alessandro D. Santin 1 1 Department of Obstet...
1 CitationsSource
#1Chanhee Han (Yale University)H-Index: 4
#2Emanuele Perrone (Yale University)H-Index: 1
Last. Alessandro D. Santin (Yale University)H-Index: 31
view all 24 authors...
Abstract Objective Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer with poor prognosis. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast cell-surface antigen 2 (Trop-2), a transmembrane-calcium-signal-transducer, to deliver SN-38, the active metabolite of irinotecan. The objective of this study was to evaluate the expression of Trop-2 in USC and the preclinical activity of SG against primary USC cell-lines and xenografts. Met...
1 CitationsSource
#1Burak Zeybek (Yale University)H-Index: 9
#2Aranzazu Manzano (Yale University)H-Index: 4
Last. Paola Manara (Yale University)H-Index: 3
view all 21 authors...
Human trophoblast cell-surface marker (Trop-2) is a surface glycoprotein originally identified in human placental tissue and subsequently found to be highly expressed by various types of human epithelial solid tumors. We investigated the efficacy of sacituzumab govitecan, an antibody-drug conjugate (ADC) comprised of a humanized anti- Trop-2 antibody, conjugated with active metabolite of irinotecan (SN-38), on Trop-2 positive cervical cancer cell lines and a xenograft model. Trop-2 expression wa...
2 CitationsSource
#1Alessandro D. Santin (Yale University)H-Index: 31
#2Wei DengH-Index: 3
Last. Michael J. Birrer (UA: University of Alabama)H-Index: 82
view all 12 authors...
Abstract Purpose Patients with persistent/recurrent cervical cancer following platinum-based chemotherapy have limited therapeutic options. The Gynecologic-Oncology-Group conducted a phase II trial to assess efficacy and tolerability of nivolumab, an immune checkpoint inhibitor, in persistent/recurrent cervical carcinoma. Patients and methods Key eligibility criteria included persistent/recurrent cervical cancer, failure of prior systemic therapy and ECOG PS 0-1. Nivolumab 3 mg/kg was given IV e...
1 CitationsSource
#2Virginia FiliaciH-Index: 8
Last. Michael J. BirrerH-Index: 82
view all 14 authors...
Abstract Purpose NRG Oncology conducted a phase II trial to assess the antitumor activity and tolerability of copanlisib, a selective inhibitor of PIK3CA, in persistent or recurrent endometrial carcinoma harboring hotspot PIK3CA mutations. Patients and methods Eligible patients had endometrial cancer with endometrioid, serous or mixed histology, a somatic PIK3CA gene mutation, measurable disease, and GOG performance status ≤2. Treatment consisted of IV copanlisib (60 mg weekly, day 1, 8 and 15 o...
Source
12345678910